博瑞医药股价涨5.03%，华夏基金旗下1只基金重仓，持有2.27万股浮盈赚取5.59万元

Group 1 - The core viewpoint of the news is that Borui Pharmaceutical's stock has increased by 5.03%, reaching a price of 51.33 CNY per share, with a trading volume of 355 million CNY and a turnover rate of 1.68%, resulting in a total market capitalization of 21.718 billion CNY [1] - Borui Pharmaceutical, established on October 26, 2001, and listed on November 8, 2019, is located in Suzhou Industrial Park, Jiangsu Province. The company focuses on the research and production of high-end generic drugs and original new drugs, with product sales accounting for 89.90% of its main business revenue [1] - The revenue composition of Borui Pharmaceutical includes 89.90% from product sales, 6.77% from technology rights and services, and 3.33% from other sources [1] Group 2 - From the perspective of major fund holdings, Huaxia Fund has a fund that heavily invests in Borui Pharmaceutical. The Huaxia SSE Sci-Tech Innovation Board Biomedicine ETF (588130) held 22,700 shares in the third quarter, representing 3.33% of the fund's net value, making it the ninth-largest holding [2] - The Huaxia SSE Sci-Tech Innovation Board Biomedicine ETF (588130) was established on May 14, 2025, with a latest scale of 40.771 million CNY and has achieved a return of 10.96% since its inception [2] - The fund manager of Huaxia SSE Sci-Tech Innovation Board Biomedicine ETF (588130) is Lu Yayun, who has been in the position for 3 years and 169 days, managing total assets of 22.81 billion CNY, with the best fund return during the tenure being 67.65% and the worst being -33.22% [2]